Browse by category

Patients with obesity who received semaglutide had a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder...

The latest analysis from the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity Trial (SELECT) has...

The results of an independent study led by Mayo Clinic has found that the MyPhenome Hungry Gut test (Phenomix Sciences) can predict a...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

An economic evaluation comparing endoscopic sleeve gastroplasty (ESG) with semaglutide for treating class II obesity has suggested ESG is...

A group of 44 health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and...

The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...

Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...

Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...

Glucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...